Showing results (471-480 of 490) with videos related to

Sort By:
Pageof 49
ESMO Open|November 28, 2024
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN studyN Girard, F Guisier, A Swalduz, et al.
Journal of Bone Oncology|June 21, 2021
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinomaE Massy, J C Rousseau, M Gueye, et al.
ESMO Open|July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysisK Amrane, B Cabarrou, G Justeau, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|October 27, 2018
[Siriade 2.0: An e-learning platform for radiation oncology contouring]J-E Bibault, F Denis, A Roué, et al.
ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
ESMO Rare Cancers|July 15, 2025
The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC): a gateway to rare cancer epidemiological researchL Fernandez-Cuesta, C Voegele, B Hemon, et al.
Orphanet Journal of Rare Diseases|May 26, 2020
Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patientsC Daccord, V Cottin, G Prévot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)S Couraud, A B Cortot, L Greillier, et al.
Pageof 49